Design and rationale of the Botswana Smoking Abstinence Reinforcement Trial: a protocol for a stepped-wedge cluster randomized trial
Background With expanded and sustained availability of HIV treatment resulting in substantial improvements in life expectancy, the need to address modifiable risk factors associated with leading causes of death among people living with HIV/AIDS (PLWH), such as tobacco smoking, has increased. Tobacco...
Saved in:
| Published in: | Implementation science communications Vol. 5; no. 1; pp. 53 - 11 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BioMed Central
08.05.2024
Springer Nature B.V BMC |
| Subjects: | |
| ISSN: | 2662-2211, 2662-2211 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
With expanded and sustained availability of HIV treatment resulting in substantial improvements in life expectancy, the need to address modifiable risk factors associated with leading causes of death among people living with HIV/AIDS (PLWH), such as tobacco smoking, has increased. Tobacco use is highly prevalent among PLWH, especially in southern Africa, where HIV is heavily concentrated, and many people who smoke would like to quit but are unable to do so without assistance. SBIRT (Screening, Brief Intervention and Referral to Treatment) is a well-established evidence-based approach successful at supporting smoking cessation in a variety of settings. Varenicline is efficacious in supporting smoking cessation. We intend to assess the effectiveness of SBIRT and varenicline on smoking cessation among PLWH in Botswana and the effectiveness of our implementation.
Methods
BSMART (Botswana Smoking Abstinence Reinforcement Trial) is a stepped-wedge, cluster randomized, hybrid Type 2 effectiveness-implementation study guided by the RE-AIM framework, to evaluate the effectiveness and implementation of an SBIRT intervention consisting of the 5As compared to an enhanced standard of care. SBIRT will be delivered by trained lay health workers (LHWs), followed by referral to treatment with varenicline prescribed and monitored by trained nurse prescribers in a network of outpatient HIV care facilities. Seven hundred and fifty people living with HIV who smoke daily and have been receiving HIV care and treatment at one of 15 health facilities will be recruited if they are up to 18 years of age and willing to provide informed consent to participate in the study.
Discussion
BSMART tests a scalable approach to achieve and sustain smoking abstinence implemented in a sustainable way. Integrating an evidence-based approach such as SBIRT, into an HIV care system presents an important opportunity to establish and evaluate a modifiable cancer prevention strategy in a middle-income country (MIC) setting where both LHW and non-physician clinicians are widely used. The findings, including the preliminary cost-effectiveness, will provide evidence to guide the Botswanan government and similar countries as they strive to provide affordable smoking cessation support at scale.
Clinical trial registration
NCT05694637 Registered on 7 December 2022 on clinicaltrials.gov,
https://clinicaltrials.gov/search?locStr=Botswana&country=Botswana&cond=Smoking%20Cessation&intr=SBIRT |
|---|---|
| AbstractList | Background
With expanded and sustained availability of HIV treatment resulting in substantial improvements in life expectancy, the need to address modifiable risk factors associated with leading causes of death among people living with HIV/AIDS (PLWH), such as tobacco smoking, has increased. Tobacco use is highly prevalent among PLWH, especially in southern Africa, where HIV is heavily concentrated, and many people who smoke would like to quit but are unable to do so without assistance. SBIRT (Screening, Brief Intervention and Referral to Treatment) is a well-established evidence-based approach successful at supporting smoking cessation in a variety of settings. Varenicline is efficacious in supporting smoking cessation. We intend to assess the effectiveness of SBIRT and varenicline on smoking cessation among PLWH in Botswana and the effectiveness of our implementation.
Methods
BSMART (Botswana Smoking Abstinence Reinforcement Trial) is a stepped-wedge, cluster randomized, hybrid Type 2 effectiveness-implementation study guided by the RE-AIM framework, to evaluate the effectiveness and implementation of an SBIRT intervention consisting of the 5As compared to an enhanced standard of care. SBIRT will be delivered by trained lay health workers (LHWs), followed by referral to treatment with varenicline prescribed and monitored by trained nurse prescribers in a network of outpatient HIV care facilities. Seven hundred and fifty people living with HIV who smoke daily and have been receiving HIV care and treatment at one of 15 health facilities will be recruited if they are up to 18 years of age and willing to provide informed consent to participate in the study.
Discussion
BSMART tests a scalable approach to achieve and sustain smoking abstinence implemented in a sustainable way. Integrating an evidence-based approach such as SBIRT, into an HIV care system presents an important opportunity to establish and evaluate a modifiable cancer prevention strategy in a middle-income country (MIC) setting where both LHW and non-physician clinicians are widely used. The findings, including the preliminary cost-effectiveness, will provide evidence to guide the Botswanan government and similar countries as they strive to provide affordable smoking cessation support at scale.
Clinical trial registration
NCT05694637 Registered on 7 December 2022 on clinicaltrials.gov,
https://clinicaltrials.gov/search?locStr=Botswana&country=Botswana&cond=Smoking%20Cessation&intr=SBIRT BackgroundWith expanded and sustained availability of HIV treatment resulting in substantial improvements in life expectancy, the need to address modifiable risk factors associated with leading causes of death among people living with HIV/AIDS (PLWH), such as tobacco smoking, has increased. Tobacco use is highly prevalent among PLWH, especially in southern Africa, where HIV is heavily concentrated, and many people who smoke would like to quit but are unable to do so without assistance. SBIRT (Screening, Brief Intervention and Referral to Treatment) is a well-established evidence-based approach successful at supporting smoking cessation in a variety of settings. Varenicline is efficacious in supporting smoking cessation. We intend to assess the effectiveness of SBIRT and varenicline on smoking cessation among PLWH in Botswana and the effectiveness of our implementation.MethodsBSMART (Botswana Smoking Abstinence Reinforcement Trial) is a stepped-wedge, cluster randomized, hybrid Type 2 effectiveness-implementation study guided by the RE-AIM framework, to evaluate the effectiveness and implementation of an SBIRT intervention consisting of the 5As compared to an enhanced standard of care. SBIRT will be delivered by trained lay health workers (LHWs), followed by referral to treatment with varenicline prescribed and monitored by trained nurse prescribers in a network of outpatient HIV care facilities. Seven hundred and fifty people living with HIV who smoke daily and have been receiving HIV care and treatment at one of 15 health facilities will be recruited if they are up to 18 years of age and willing to provide informed consent to participate in the study.DiscussionBSMART tests a scalable approach to achieve and sustain smoking abstinence implemented in a sustainable way. Integrating an evidence-based approach such as SBIRT, into an HIV care system presents an important opportunity to establish and evaluate a modifiable cancer prevention strategy in a middle-income country (MIC) setting where both LHW and non-physician clinicians are widely used. The findings, including the preliminary cost-effectiveness, will provide evidence to guide the Botswanan government and similar countries as they strive to provide affordable smoking cessation support at scale.Clinical trial registrationNCT05694637 Registered on 7 December 2022 on clinicaltrials.gov, https://clinicaltrials.gov/search?locStr=Botswana&country=Botswana&cond=Smoking%20Cessation&intr=SBIRT With expanded and sustained availability of HIV treatment resulting in substantial improvements in life expectancy, the need to address modifiable risk factors associated with leading causes of death among people living with HIV/AIDS (PLWH), such as tobacco smoking, has increased. Tobacco use is highly prevalent among PLWH, especially in southern Africa, where HIV is heavily concentrated, and many people who smoke would like to quit but are unable to do so without assistance. SBIRT (Screening, Brief Intervention and Referral to Treatment) is a well-established evidence-based approach successful at supporting smoking cessation in a variety of settings. Varenicline is efficacious in supporting smoking cessation. We intend to assess the effectiveness of SBIRT and varenicline on smoking cessation among PLWH in Botswana and the effectiveness of our implementation.BACKGROUNDWith expanded and sustained availability of HIV treatment resulting in substantial improvements in life expectancy, the need to address modifiable risk factors associated with leading causes of death among people living with HIV/AIDS (PLWH), such as tobacco smoking, has increased. Tobacco use is highly prevalent among PLWH, especially in southern Africa, where HIV is heavily concentrated, and many people who smoke would like to quit but are unable to do so without assistance. SBIRT (Screening, Brief Intervention and Referral to Treatment) is a well-established evidence-based approach successful at supporting smoking cessation in a variety of settings. Varenicline is efficacious in supporting smoking cessation. We intend to assess the effectiveness of SBIRT and varenicline on smoking cessation among PLWH in Botswana and the effectiveness of our implementation.BSMART (Botswana Smoking Abstinence Reinforcement Trial) is a stepped-wedge, cluster randomized, hybrid Type 2 effectiveness-implementation study guided by the RE-AIM framework, to evaluate the effectiveness and implementation of an SBIRT intervention consisting of the 5As compared to an enhanced standard of care. SBIRT will be delivered by trained lay health workers (LHWs), followed by referral to treatment with varenicline prescribed and monitored by trained nurse prescribers in a network of outpatient HIV care facilities. Seven hundred and fifty people living with HIV who smoke daily and have been receiving HIV care and treatment at one of 15 health facilities will be recruited if they are up to 18 years of age and willing to provide informed consent to participate in the study.METHODSBSMART (Botswana Smoking Abstinence Reinforcement Trial) is a stepped-wedge, cluster randomized, hybrid Type 2 effectiveness-implementation study guided by the RE-AIM framework, to evaluate the effectiveness and implementation of an SBIRT intervention consisting of the 5As compared to an enhanced standard of care. SBIRT will be delivered by trained lay health workers (LHWs), followed by referral to treatment with varenicline prescribed and monitored by trained nurse prescribers in a network of outpatient HIV care facilities. Seven hundred and fifty people living with HIV who smoke daily and have been receiving HIV care and treatment at one of 15 health facilities will be recruited if they are up to 18 years of age and willing to provide informed consent to participate in the study.BSMART tests a scalable approach to achieve and sustain smoking abstinence implemented in a sustainable way. Integrating an evidence-based approach such as SBIRT, into an HIV care system presents an important opportunity to establish and evaluate a modifiable cancer prevention strategy in a middle-income country (MIC) setting where both LHW and non-physician clinicians are widely used. The findings, including the preliminary cost-effectiveness, will provide evidence to guide the Botswanan government and similar countries as they strive to provide affordable smoking cessation support at scale.DISCUSSIONBSMART tests a scalable approach to achieve and sustain smoking abstinence implemented in a sustainable way. Integrating an evidence-based approach such as SBIRT, into an HIV care system presents an important opportunity to establish and evaluate a modifiable cancer prevention strategy in a middle-income country (MIC) setting where both LHW and non-physician clinicians are widely used. The findings, including the preliminary cost-effectiveness, will provide evidence to guide the Botswanan government and similar countries as they strive to provide affordable smoking cessation support at scale.NCT05694637 Registered on 7 December 2022 on clinicaltrials.gov, https://clinicaltrials.gov/search?locStr=Botswana&country=Botswana&cond=Smoking%20Cessation&intr=SBIRT.CLINICAL TRIAL REGISTRATIONNCT05694637 Registered on 7 December 2022 on clinicaltrials.gov, https://clinicaltrials.gov/search?locStr=Botswana&country=Botswana&cond=Smoking%20Cessation&intr=SBIRT. Abstract Background With expanded and sustained availability of HIV treatment resulting in substantial improvements in life expectancy, the need to address modifiable risk factors associated with leading causes of death among people living with HIV/AIDS (PLWH), such as tobacco smoking, has increased. Tobacco use is highly prevalent among PLWH, especially in southern Africa, where HIV is heavily concentrated, and many people who smoke would like to quit but are unable to do so without assistance. SBIRT (Screening, Brief Intervention and Referral to Treatment) is a well-established evidence-based approach successful at supporting smoking cessation in a variety of settings. Varenicline is efficacious in supporting smoking cessation. We intend to assess the effectiveness of SBIRT and varenicline on smoking cessation among PLWH in Botswana and the effectiveness of our implementation. Methods BSMART (Botswana Smoking Abstinence Reinforcement Trial) is a stepped-wedge, cluster randomized, hybrid Type 2 effectiveness-implementation study guided by the RE-AIM framework, to evaluate the effectiveness and implementation of an SBIRT intervention consisting of the 5As compared to an enhanced standard of care. SBIRT will be delivered by trained lay health workers (LHWs), followed by referral to treatment with varenicline prescribed and monitored by trained nurse prescribers in a network of outpatient HIV care facilities. Seven hundred and fifty people living with HIV who smoke daily and have been receiving HIV care and treatment at one of 15 health facilities will be recruited if they are up to 18 years of age and willing to provide informed consent to participate in the study. Discussion BSMART tests a scalable approach to achieve and sustain smoking abstinence implemented in a sustainable way. Integrating an evidence-based approach such as SBIRT, into an HIV care system presents an important opportunity to establish and evaluate a modifiable cancer prevention strategy in a middle-income country (MIC) setting where both LHW and non-physician clinicians are widely used. The findings, including the preliminary cost-effectiveness, will provide evidence to guide the Botswanan government and similar countries as they strive to provide affordable smoking cessation support at scale. Clinical trial registration NCT05694637 Registered on 7 December 2022 on clinicaltrials.gov, https://clinicaltrials.gov/search?locStr=Botswana&country=Botswana&cond=Smoking%20Cessation&intr=SBIRT With expanded and sustained availability of HIV treatment resulting in substantial improvements in life expectancy, the need to address modifiable risk factors associated with leading causes of death among people living with HIV/AIDS (PLWH), such as tobacco smoking, has increased. Tobacco use is highly prevalent among PLWH, especially in southern Africa, where HIV is heavily concentrated, and many people who smoke would like to quit but are unable to do so without assistance. SBIRT (Screening, Brief Intervention and Referral to Treatment) is a well-established evidence-based approach successful at supporting smoking cessation in a variety of settings. Varenicline is efficacious in supporting smoking cessation. We intend to assess the effectiveness of SBIRT and varenicline on smoking cessation among PLWH in Botswana and the effectiveness of our implementation. BSMART (Botswana Smoking Abstinence Reinforcement Trial) is a stepped-wedge, cluster randomized, hybrid Type 2 effectiveness-implementation study guided by the RE-AIM framework, to evaluate the effectiveness and implementation of an SBIRT intervention consisting of the 5As compared to an enhanced standard of care. SBIRT will be delivered by trained lay health workers (LHWs), followed by referral to treatment with varenicline prescribed and monitored by trained nurse prescribers in a network of outpatient HIV care facilities. Seven hundred and fifty people living with HIV who smoke daily and have been receiving HIV care and treatment at one of 15 health facilities will be recruited if they are up to 18 years of age and willing to provide informed consent to participate in the study. BSMART tests a scalable approach to achieve and sustain smoking abstinence implemented in a sustainable way. Integrating an evidence-based approach such as SBIRT, into an HIV care system presents an important opportunity to establish and evaluate a modifiable cancer prevention strategy in a middle-income country (MIC) setting where both LHW and non-physician clinicians are widely used. The findings, including the preliminary cost-effectiveness, will provide evidence to guide the Botswanan government and similar countries as they strive to provide affordable smoking cessation support at scale. NCT05694637 Registered on 7 December 2022 on clinicaltrials.gov, https://clinicaltrials.gov/search?locStr=Botswana&country=Botswana&cond=Smoking%20Cessation&intr=SBIRT. |
| ArticleNumber | 53 |
| Author | Montebatsi, Milton DiClemente, Carlo Magidson, Jessica F. Onukwugha, Eberechukwu Bada, Florence Ikgopoleng, Kaizer Charurat, Man Okui, Lillian Mansfield, Megan E. Ndwapi, Ndwapi Tapera, Roy Mokonopi, Selebaleng Mbongwe, Bontle Himelhoch, Seth |
| Author_xml | – sequence: 1 givenname: Florence orcidid: 0000-0002-0212-3907 surname: Bada fullname: Bada, Florence email: FBada@ihv.umaryland.edu organization: Division of Epidemiology and Prevention, Institute of Human Virology, University of Maryland School of Medicine – sequence: 2 givenname: Megan E. surname: Mansfield fullname: Mansfield, Megan E. organization: Division of Epidemiology and Prevention, Institute of Human Virology, University of Maryland School of Medicine – sequence: 3 givenname: Lillian surname: Okui fullname: Okui, Lillian organization: Botswana University of Maryland Medicine Health Initiative – sequence: 4 givenname: Milton surname: Montebatsi fullname: Montebatsi, Milton organization: Botswana University of Maryland Medicine Health Initiative – sequence: 5 givenname: Carlo surname: DiClemente fullname: DiClemente, Carlo organization: Department of Psychology, University of Maryland Baltimore County – sequence: 6 givenname: Roy surname: Tapera fullname: Tapera, Roy organization: School of Public Health, University of Botswana, Anti-Tobacco Network, University of Botswana – sequence: 7 givenname: Kaizer surname: Ikgopoleng fullname: Ikgopoleng, Kaizer organization: Botswana University of Maryland Medicine Health Initiative – sequence: 8 givenname: Selebaleng surname: Mokonopi fullname: Mokonopi, Selebaleng organization: Botswana University of Maryland Medicine Health Initiative – sequence: 9 givenname: Jessica F. surname: Magidson fullname: Magidson, Jessica F. organization: Department of Psychology and the Center for Substance Use, Addiction & Health Research (CESAR), University of Maryland – sequence: 10 givenname: Eberechukwu surname: Onukwugha fullname: Onukwugha, Eberechukwu organization: Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy – sequence: 11 givenname: Ndwapi surname: Ndwapi fullname: Ndwapi, Ndwapi organization: Botswana University of Maryland Medicine Health Initiative – sequence: 12 givenname: Seth surname: Himelhoch fullname: Himelhoch, Seth organization: Department of Psychiatry, University of Kentucky School of Medicine – sequence: 13 givenname: Bontle surname: Mbongwe fullname: Mbongwe, Bontle organization: School of Public Health, University of Botswana, Anti-Tobacco Network, University of Botswana – sequence: 14 givenname: Man surname: Charurat fullname: Charurat, Man organization: Division of Epidemiology and Prevention, Institute of Human Virology, University of Maryland School of Medicine, Department of Epidemiology and Public Health, University of Maryland School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38720363$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UstuFDEQtFAQCUt-gAOyxIXLgF874-GCQnhFioQE4Wz50TPxMmMvtpcIznw4zm4ISQ45ud1dVd1212O0F2IAhJ5S8pJS2b7KgpOlbAgTDamBbLoH6IC1LWsYo3TvRryPDnNeEULYklJBxCO0z2XHCG_5AfrzDrIfA9bB4aSLj0FPgOOAyzngt7HkCx00_jrH7z6M-Mjk4gMEC_gL-DDEZGGGUPBZ8np6jTVep1iijROutXrNBdZrcM0FuBGwnTY1kWqj4OLsf4PD5ZL4BD0c9JTh8OpcoG8f3p8df2pOP388OT46bWxLZGmEdQDO2X7gsh8YA91xAmxwxhCppROSukE6ynvTGi4c161jpLfSLk1vrOULdLLTdVGv1Dr5WadfKmqvtomYRqVT8XYCJWULLV1yKzkVvTbSGSaho3wptZBGVK03O631xszgbP2FpKdborcrwZ-rMf5UlJKuk7yvCi-uFFL8sYFc1OyzhWnSAeImq7pfTnkrKniBnt-BruIm1VVVFG1lL_oKrKhnN0e6nuXftiuA7QA2xZwTDNcQStSlq9TOVaq6Sm1dpbpKkndI1petU-qz_HQ_le-oufYJI6T_Y9_D-gtMn-Mu |
| CitedBy_id | crossref_primary_10_1007_s10461_025_04823_7 |
| Cites_doi | 10.1111/add.14518 10.1093/ntr/ntv014 10.1002/hec.843 10.2165/11584630-000000000-00000 10.1097/00002030-199305000-00015 10.2165/00019053-200725100-00001 10.1016/j.jemermed.2008.03.034 10.1136/bmj.h391 10.1521/aeap.2009.21.3_supp.40 10.1086/314048 10.1016/j.amepre.2008.04.009 10.1016/S2214-109X(17)30170-5 10.1016/j.jana.2009.03.007 10.1378/chest.108.4.946 10.1097/COH.0b013e328347876c 10.1097/ADM.0000000000000172 10.2105/AJPH.89.9.1322 10.1097/COH.0000000000000306 10.1097/00000658-199910000-00003 10.1086/375844 10.1016/j.amepre.2007.09.035 10.1097/COH.0000000000000298 10.1080/14622200500186064 10.1007/s40273-020-00983-7 10.2105/AJPH.2009.188664 10.1002/sim.4780131106 10.1097/QAI.0b013e318278f3fa 10.1097/QAD.0000000000000540 10.1016/j.drugalcdep.2019.03.011 10.1007/s11904-012-0121-0 10.1378/chest.12-1699 10.1186/1741-7015-11-15 10.1016/j.jana.2013.04.005 10.1136/tobaccocontrol-2011-050147 10.1001/jama.2020.25019 10.1016/S0140-6736(16)30272-0 10.1093/infdis/jiw430 10.1016/j.cct.2006.05.007 10.1111/j.1553-2712.2009.00552.x 10.1111/j.1468-1293.2009.00735.x 10.1093/infdis/jiw434 10.1186/s13722-015-0047-0 10.1111/j.1360-0443.2009.02623.x 10.1016/j.addbeh.2013.05.003 10.1037/adb0000318 10.1097/MLR.0b013e3182408812 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| DBID | C6C AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s43058-024-00588-7 |
| DatabaseName | Springer Nature Link CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest One Health & Nursing ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 2662-2211 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_886e6153c83149ab8db28e71358a48b4 PMC11077839 38720363 10_1186_s43058_024_00588_7 |
| Genre | Journal Article |
| GeographicLocations | United States--US Botswana |
| GeographicLocations_xml | – name: United States--US – name: Botswana |
| GrantInformation_xml | – fundername: National Cancer Institute, National Institutes of Health grantid: 1U01CA275048-01 |
| GroupedDBID | 0R~ 7X7 8FI 8FJ AAFWJ AAJSJ AASML ABUWG ADBBV ADUKV AFKRA AFPKN ALMA_UNASSIGNED_HOLDINGS BENPR BFQNJ BMC C6C CCPQU EBLON EBS EJD FYUFA GROUPED_DOAJ HMCUK IAO IGS ITC M~E OK1 PGMZT PHGZM PHGZT PIMPY PUEGO ROL RPM RSV SOJ UKHRP AAYXX AFFHD CITATION ALIPV NPM 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c608t-4cdeeddc9f389f22ea730e2fdbb08a8d481df8d139b6b34d3a6d209c8c5b9bcc3 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001218988500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2662-2211 |
| IngestDate | Tue Oct 14 19:04:47 EDT 2025 Tue Nov 04 02:05:29 EST 2025 Fri Sep 05 06:57:45 EDT 2025 Sat Oct 18 23:17:01 EDT 2025 Mon Jul 21 06:03:10 EDT 2025 Tue Nov 18 22:15:40 EST 2025 Sat Nov 29 02:10:10 EST 2025 Sat Sep 06 07:29:10 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Smoking cessation Brief intervention Type 2 hybrid effectiveness-implementation Varenicline |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c608t-4cdeeddc9f389f22ea730e2fdbb08a8d481df8d139b6b34d3a6d209c8c5b9bcc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-0212-3907 |
| OpenAccessLink | https://www.proquest.com/docview/3168949136?pq-origsite=%requestingapplication% |
| PMID | 38720363 |
| PQID | 3168949136 |
| PQPubID | 5068529 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_886e6153c83149ab8db28e71358a48b4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11077839 proquest_miscellaneous_3053136478 proquest_journals_3168949136 pubmed_primary_38720363 crossref_primary_10_1186_s43058_024_00588_7 crossref_citationtrail_10_1186_s43058_024_00588_7 springer_journals_10_1186_s43058_024_00588_7 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-05-08 |
| PublicationDateYYYYMMDD | 2024-05-08 |
| PublicationDate_xml | – month: 05 year: 2024 text: 2024-05-08 day: 08 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Implementation science communications |
| PublicationTitleAbbrev | Implement Sci Commun |
| PublicationTitleAlternate | Implement Sci Commun |
| PublicationYear | 2024 |
| Publisher | BioMed Central Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: Springer Nature B.V – name: BMC |
| References | M Fiore (588_CR24) 2008; 35 SL Bernstein (588_CR27) 2010; 38 GM Curran (588_CR42) 2012; 50 KP Reddy (588_CR4) 2016; 214 P De (588_CR17) 2013; 11 KL Cropsey (588_CR28) 2013; 38 AR Willan (588_CR47) 2004; 13 RM Cunningham (588_CR30) 2009; 16 R Jain (588_CR48) 2011; 29 TA Winston (588_CR16) 2013; 143 588_CR26 EE Lloyd-Richardson (588_CR33) 2009; 104 CC Diclemente (588_CR29) 2017; 31 A Calhoun (588_CR43) 2014; 2014 AH Krist (588_CR32) 2021; 325 KN Althoff (588_CR2) 2016; 214 D Méndez (588_CR39) 2013; 22 M Fuster (588_CR22) 2009; 10 SR Lipsitz (588_CR45) 1994; 13 CA Stanton (588_CR34) 2015; 17 JE Burkhalter (588_CR7) 2005; 7 RB Nieman (588_CR11) 1993; 7 AR Lifson (588_CR9) 2012; 9 M Savès (588_CR14) 2003; 37 K Crothers (588_CR19) 2009; 21 KL Cropsey (588_CR12) 2016; 10 RE Glasgow (588_CR40) 1999; 89 ML Metersky (588_CR13) 1995; 108 M Helleberg (588_CR21) 2015; 29 J Kwong (588_CR5) 2010; 21 J Shuter (588_CR23) 2021; 14 588_CR41 RL Ashare (588_CR36) 2018; 2019 FJ Palella (588_CR15) 2011; 6 K Petoumenos (588_CR3) 2016; 11 R Niaura (588_CR6) 2000; 31 JR Mertens (588_CR31) 2015; 10 RM Anthenelli (588_CR35) 2016; 387 ND Mdege (588_CR10) 2017; 5 MA Hussey (588_CR44) 2007; 28 G Wandeler (588_CR1) 2016; 11 G Moscou-Jackson (588_CR8) 2014; 25 KM Akgün (588_CR18) 2013; 62 LM Gentilello (588_CR25) 1999; 230 C McCabe (588_CR49) 2021; 39 JS Hoch (588_CR46) 2007; 25 588_CR37 MO Akanbi (588_CR50) 2019; 114 AR Lifson (588_CR20) 2010; 100 588_CR38 |
| References_xml | – volume: 114 start-page: 620 issue: 4 year: 2019 ident: 588_CR50 publication-title: Addiction doi: 10.1111/add.14518 – volume: 17 start-page: 975 issue: 8 year: 2015 ident: 588_CR34 publication-title: Nicotine Tob Res doi: 10.1093/ntr/ntv014 – volume: 13 start-page: 461 issue: 5 year: 2004 ident: 588_CR47 publication-title: Health Econ doi: 10.1002/hec.843 – volume: 29 start-page: 297 issue: 4 year: 2011 ident: 588_CR48 publication-title: Pharmacoeconomics doi: 10.2165/11584630-000000000-00000 – volume: 7 start-page: 705 year: 1993 ident: 588_CR11 publication-title: Aids doi: 10.1097/00002030-199305000-00015 – volume: 25 start-page: 807 issue: 10 year: 2007 ident: 588_CR46 publication-title: Pharmacoeconomics doi: 10.2165/00019053-200725100-00001 – volume: 38 start-page: e35 issue: 4 year: 2010 ident: 588_CR27 publication-title: J Emerg Med doi: 10.1016/j.jemermed.2008.03.034 – ident: 588_CR41 doi: 10.1136/bmj.h391 – volume: 21 start-page: 40 issue: SUPPL. 3 year: 2009 ident: 588_CR19 publication-title: AIDS Educ Prev doi: 10.1521/aeap.2009.21.3_supp.40 – ident: 588_CR38 – ident: 588_CR37 – volume: 31 start-page: 808 issue: 3 year: 2000 ident: 588_CR6 publication-title: Clin Infect Dis doi: 10.1086/314048 – volume: 35 start-page: 158 issue: 2 year: 2008 ident: 588_CR24 publication-title: Am J Prev Med. doi: 10.1016/j.amepre.2008.04.009 – volume: 5 start-page: 92 issue: 6 year: 2017 ident: 588_CR10 publication-title: Lancet Glob Heal doi: 10.1016/S2214-109X(17)30170-5 – volume: 21 start-page: 3 issue: 1 year: 2010 ident: 588_CR5 publication-title: J Assoc Nurses AIDS Care doi: 10.1016/j.jana.2009.03.007 – volume: 108 start-page: 946 issue: 4 year: 1995 ident: 588_CR13 publication-title: Chest doi: 10.1378/chest.108.4.946 – volume: 6 start-page: 266 issue: 4 year: 2011 ident: 588_CR15 publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0b013e328347876c – volume: 10 start-page: 13 issue: 1 year: 2016 ident: 588_CR12 publication-title: J Addict Med doi: 10.1097/ADM.0000000000000172 – volume: 89 start-page: 1322 issue: 9 year: 1999 ident: 588_CR40 publication-title: Am J Public Health doi: 10.2105/AJPH.89.9.1322 – volume: 11 start-page: 514 issue: 5 year: 2016 ident: 588_CR3 publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0000000000000306 – volume: 230 start-page: 473 issue: 4 year: 1999 ident: 588_CR25 publication-title: Ann Surg doi: 10.1097/00000658-199910000-00003 – volume: 37 start-page: 292 issue: 2 year: 2003 ident: 588_CR14 publication-title: Clin Infect Dis doi: 10.1086/375844 – volume: 2014 start-page: 1 issue: 11 year: 2014 ident: 588_CR43 publication-title: Prev Chronic Dis – ident: 588_CR26 doi: 10.1016/j.amepre.2007.09.035 – volume: 11 start-page: 492 issue: 5 year: 2016 ident: 588_CR1 publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0000000000000298 – volume: 7 start-page: 511 issue: 4 year: 2005 ident: 588_CR7 publication-title: Nicotine Tob Res doi: 10.1080/14622200500186064 – volume: 39 start-page: 19 issue: 1 year: 2021 ident: 588_CR49 publication-title: Pharmacoeconomics doi: 10.1007/s40273-020-00983-7 – volume: 100 start-page: 1896 issue: 10 year: 2010 ident: 588_CR20 publication-title: Am J Public Health doi: 10.2105/AJPH.2009.188664 – volume: 13 start-page: 1149 issue: 11 year: 1994 ident: 588_CR45 publication-title: Stat Med doi: 10.1002/sim.4780131106 – volume: 62 start-page: 52 issue: 1 year: 2013 ident: 588_CR18 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e318278f3fa – volume: 29 start-page: 221 issue: 2 year: 2015 ident: 588_CR21 publication-title: AIDS doi: 10.1097/QAD.0000000000000540 – volume: 2019 start-page: 26 issue: 200 year: 2018 ident: 588_CR36 publication-title: Drug Alcohol Depend doi: 10.1016/j.drugalcdep.2019.03.011 – volume: 9 start-page: 223 issue: 3 year: 2012 ident: 588_CR9 publication-title: Curr HIV/AIDS Rep doi: 10.1007/s11904-012-0121-0 – volume: 143 start-page: 305 issue: 2 year: 2013 ident: 588_CR16 publication-title: Chest. doi: 10.1378/chest.12-1699 – volume: 14 start-page: 1179173X2110533 year: 2021 ident: 588_CR23 publication-title: Kenya. Tob Use Insights – volume: 11 start-page: 15 issue: 1 year: 2013 ident: 588_CR17 publication-title: BMC Med doi: 10.1186/1741-7015-11-15 – volume: 25 start-page: 32 issue: 1 year: 2014 ident: 588_CR8 publication-title: J Assoc Nurses AIDS Care doi: 10.1016/j.jana.2013.04.005 – volume: 22 start-page: 46 issue: 1 year: 2013 ident: 588_CR39 publication-title: Tob Control doi: 10.1136/tobaccocontrol-2011-050147 – volume: 325 start-page: 265 issue: 3 year: 2021 ident: 588_CR32 publication-title: JAMA doi: 10.1001/jama.2020.25019 – volume: 387 start-page: 2507 issue: 10037 year: 2016 ident: 588_CR35 publication-title: Lancet doi: 10.1016/S0140-6736(16)30272-0 – volume: 214 start-page: 1672 issue: 11 year: 2016 ident: 588_CR4 publication-title: J Infect Dis doi: 10.1093/infdis/jiw430 – volume: 28 start-page: 182 issue: 2 year: 2007 ident: 588_CR44 publication-title: Contemp Clin Trials doi: 10.1016/j.cct.2006.05.007 – volume: 16 start-page: 1078 issue: 11 year: 2009 ident: 588_CR30 publication-title: Acad Emerg Med doi: 10.1111/j.1553-2712.2009.00552.x – volume: 10 start-page: 614 issue: 10 year: 2009 ident: 588_CR22 publication-title: HIV Med doi: 10.1111/j.1468-1293.2009.00735.x – volume: 214 start-page: 1618 issue: 11 year: 2016 ident: 588_CR2 publication-title: J Infect Dis doi: 10.1093/infdis/jiw434 – volume: 10 start-page: 1 issue: 1 year: 2015 ident: 588_CR31 publication-title: Addict Sci Clin Pract doi: 10.1186/s13722-015-0047-0 – volume: 104 start-page: 1891 issue: 11 year: 2009 ident: 588_CR33 publication-title: Addiction doi: 10.1111/j.1360-0443.2009.02623.x – volume: 38 start-page: 2541 issue: 10 year: 2013 ident: 588_CR28 publication-title: Addict Behav doi: 10.1016/j.addbeh.2013.05.003 – volume: 31 start-page: 862 issue: 8 year: 2017 ident: 588_CR29 publication-title: Psychol Addict Behav doi: 10.1037/adb0000318 – volume: 50 start-page: 217 issue: 3 year: 2012 ident: 588_CR42 publication-title: Med Care doi: 10.1097/MLR.0b013e3182408812 |
| SSID | ssj0002511404 |
| Score | 2.2623382 |
| Snippet | Background
With expanded and sustained availability of HIV treatment resulting in substantial improvements in life expectancy, the need to address modifiable... With expanded and sustained availability of HIV treatment resulting in substantial improvements in life expectancy, the need to address modifiable risk factors... BackgroundWith expanded and sustained availability of HIV treatment resulting in substantial improvements in life expectancy, the need to address modifiable... Abstract Background With expanded and sustained availability of HIV treatment resulting in substantial improvements in life expectancy, the need to address... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 53 |
| SubjectTerms | Abstinence Brief intervention Clinics Drug therapy Health Administration Health facilities Health Policy Health Promotion and Disease Prevention Health Services Research HIV Hospitals Human immunodeficiency virus Intervention Medicine Medicine & Public Health Public Health Smoking cessation Standard of care Study Protocol Tobacco Type 2 hybrid effectiveness-implementation Varenicline |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hqgckhCjPQIuMxA2sZpNsMubWFioOqEJQpN4sP8VKbbLaRyv1zA9nxskuXZ4XjokdxfJ8Y38e298AvESMY3RBySIqWqCUJpeEGy-Dyo0bxcZFlyz9oTk5wbMz9fFGqi8-E9bLA_cdt49YByYlDksi88aitwUGTiyHpkKblECJ9dxYTPEYzMS5yqvVLRms9-esbYWSpiTJqfRQNhszURLs_x3L_PWw5E87pmkiOr4HdwcGKQ76lu_ArdDehzt9-E30t4oewLe36WSGMK0XsyHeF0QXBfE9cdgt5lemNeLzRceRcnFgydFb9nHxKSQpVZeihuKU4flGGMFyDh1hRlAZPRI0ptPg5RVH44Q7X7LcAv2o9d3F5Dp4kZKBPIQvx-9Oj97LIeGCdHWOC1k5T1OmdyoSjYlFEQz5fyiitzZHg74ichvRE2m0tS0rX5raF7ly6MZWWefKR7DVdm14AoLM5nmAMK6JVc5G46N0IcSoauXDKIPRqvO1G9TIOSnGuU6rEqx1bzBNBtPJYLrJ4NX6m2mvxfHX2ods03VN1tFOLwhdekCX_he6MthdIUIPzj3XnOtLVWpU1hm8WBeTW_Jei2lDt6Q6PLixNj9m8LgH0LolJfLed11mgBvQ2mjqZkk7-Zqkv3m13hCnzeD1CoU_2vXnvnj6P_riGdwukvuMZY67sLWYLcMebLvLxWQ-e5787zv0FjPW priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BQagS4lEoBAoyEjewyCbZZMytBSoOUKG2oN4ixw9YqU1Wm10qceaHM-M80EJBguPGjnbkfPPwjP0NwFNEP0XjlEy8og1KqmNJuLHSqVibiS-MN-FLvysODvDkRH3oL4W1w2n3oSQZLHVQa8xftExOhZJ8iuReeCiLy3CF3B2yOh4efRozKxw0Z3E23JC58NU1LxTI-i-KMH8_KPlLtTQ4of2b_yf-LbjRB51it0PJbbjk6i249r4vq2_B9S55J7o7SXfg--twrkPo2opFny10ovGCokWx1yzbc11rcXTWcJ5d7FZkJmq2EOLQBSJWE3KO4pjB_VJowWQQDSFO0Bj9JGDN587Kc87lCXO6YrIG-qPaNmezb86K0ErkLnzcf3P86q3s2zVIk8e4lJmx5HCtUZ6CIJ8kTpP1cIm3VRWjRptRaOzRUshZ5VWa2VTnNomVQTOtVGVMug0bdVO7-yAQc8vmRZvCZzHaiq_7onPeq1xZN4lgMny-0vRc5txS47QMexrMy265S1ruMix3WUTwbHxn3jF5_HX2HqNinMks3OFBs_hc9kpdkpiOA2aDKW00dcWCouOmh6gzrLIIdgZMlb1paEvuFKYyNUnzCJ6Mw6TUXKnRtWtWNIdNIzP7YwT3OgiOkqTIlfM8jQDXwLkm6vpIPfsSiMN5r19QRBzB8wGjP-X681o8-LfpD2EzCTCfyhh3YGO5WLlHcNV8Xc7axeOgqz8AQqc8Qw priority: 102 providerName: Springer Nature |
| Title | Design and rationale of the Botswana Smoking Abstinence Reinforcement Trial: a protocol for a stepped-wedge cluster randomized trial |
| URI | https://link.springer.com/article/10.1186/s43058-024-00588-7 https://www.ncbi.nlm.nih.gov/pubmed/38720363 https://www.proquest.com/docview/3168949136 https://www.proquest.com/docview/3053136478 https://pubmed.ncbi.nlm.nih.gov/PMC11077839 https://doaj.org/article/886e6153c83149ab8db28e71358a48b4 |
| Volume | 5 |
| WOSCitedRecordID | wos001218988500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Open Access Full Text customDbUrl: eissn: 2662-2211 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002511404 issn: 2662-2211 databaseCode: DOA dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2662-2211 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002511404 issn: 2662-2211 databaseCode: M~E dateStart: 20200101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2662-2211 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002511404 issn: 2662-2211 databaseCode: 7X7 dateStart: 20200101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2662-2211 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002511404 issn: 2662-2211 databaseCode: BENPR dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content customDbUrl: eissn: 2662-2211 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002511404 issn: 2662-2211 databaseCode: PIMPY dateStart: 20200101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 2662-2211 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002511404 issn: 2662-2211 databaseCode: RSV dateStart: 20201201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB6xXQ5IiPcjsFRG4gbWpkmaTLigLewKJKiq7oLKKXL8gEq7SemDlTjzw5lx0q7KYy9cIjl2lEnm83g8tr8BeIbo-qhtLiOX0wQlVqEk3Bhp81Dpnsu0017T77PhECeTfNQG3Bbttsq1TfSG2tSaY-T7nGApT_JenL6afZOcNYpXV9sUGjuwy0xlSQd2B4fD0XgTZWEHOgmT9WkZTPcXzHGFkoYmySn1UGZbI5In7v-bt_nnpsnfVk79gHR0838_5RbcaF1RcdBg5zZcsdUduN7E8URzPOku_Hzjt3gIVRkxbwOHVtROkOMoBvVyca4qJY7Pag65i4OSLEbFxkKMredk1T78KE4Y5y-FEswLURP4BNVRkTA2m1kjzzmsJ_Tpinkb6EWVqc-mP6wRPqvIPfh4dHjy-q1sMzdInYa4lIk2NPYanTvyh1wUWUWGxEbOlGWICk1CXrJDQ95nmZZxYmKVmijMNep-mZdax_ehU9WVfQgCMTVsaZTOXBKiKfnkL1rrXJ7mxvYC6K21V-iW1pyza5wWfnqDadFovCCNF17jRRbA880zs4bU49LWAwbFpiUTcvsb9fxL0fbvgsS07DtrjGnOqUoWFC3nP0SVYJkEsLfGQtFaiUVxAYQAnm6qqX_zoo2qbL2iNmwlmeQfA3jQIHAjSYy8iJ7GAeAWNrdE3a6ppl89hzhP-zNyjgN4sYbxhVz__hePLv-Mx3At8j2rL0Pcg85yvrJP4Kr-vpwu5l3YySaZv2K37ahdHwOh0ujdh9FnKo2PP_0CbINJ0g |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9NAFB6VFAkkxL4YCgwSnGBUx3bsZySEWkrVqGkUQSqVkxnPApFaO2QhgjO_h9_Ie2M7VVh664FjMpPkZfy9dWbex9hTANsBZVIR2BQTlFD6AnGjhUl9qdo2UVa5J91L-n04OkoHa-xncxeGjlU2NtEZal0qqpFvEsFSGqXtMH49_iKINYp2VxsKjQoW--bbAlO26avuDj7fZ0Gw-3b4Zk_UrAJCxT7MRKQ0-gWtUou-2gaBkQhyE1id5z5I0BFGcBY0RkZ5nIeRDmWsAz9VoDp5misV4vdeYOsRgh1abH3QPRh8WFZ1KGCP_Ki5nQPx5pR6aoFAVyiIwg9EsuIBHVHA36LbPw9p_rZT6xzg7rX_bemus6t1qM23Kt24wdZMcZNdqeqUvLp-dYv92HFHWLgsNJ_UhVHDS8sxMObb5Wy6kIXk709K2lLgWzlaxIKMIX9nXM9Z5cqrfEh6_JJLTn0vSlQujmP4EnVoPDZaLKhsydXxnPpS4A8VujwZfTeaO9aU2-zwXBbiDmsVZWHuMQ4Qa7KkUiU28kHndLMZjLE2jVNt2h5rN2jJVN22ndhDjjOXvkGcVQjLEGGZQ1iWeOz58jPjqmnJmbO3CYTLmdRw3L1RTj5ltf3KUExDuYGCEHNqmZOgYIjfEWQEeeSxjQZ7WW0Fp9kp8Dz2ZDmM9os2pWRhyjnOIS9AJAbgsbsV4peShECHBOLQY7CiCyuiro4Uo8-uRzqVNRIM_j32olGbU7n-vRb3z_4bj9mlveFBL-t1-_sP2OXAaXVH-LDBWrPJ3DxkF9XX2Wg6eVQbBs4-nrdC_QIR-aWn |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF6VFqFKiHfBUGCR4ASrOLZjj5EQagkRUUsUQSuVk1nvAyK1dsiDCM78Kn4dM2s7VXj01gPHZDfJZP1989rdGcYeA9gOKJOKwKYYoITSF4gbLUzqS9W2ibLKPen9ZDCAo6N0uMZ-Nndh6FhloxOdotalohx5ixospVHaDuOWrY9FDLu9l-MvgjpI0U5r006jgsie-bbA8G36ot_FZ_0kCHqvD169EXWHAaFiH2YiUhpthFapRbttg8BIBLwJrM5zHyToCL05Cxq9pDzOw0iHMtaBnypQnTzNlQrxey-wDXTJI-TYxrD_dvhhmeEh5z3yo-amDsStKdXXAoFmUVA7PxDJijV0TQP-5un-eWDzt11bZwx7V__nZbzGrtQuON-pOHOdrZniBrtc5S95dS3rJvvRdUdbuCw0n9QJU8NLy9Fh5rvlbLqQheTvT0raauA7OWrKgpQkf2dcLVrl0q78gPj9nEtO9TBKJB3HMXyJ3BqPjRYLSmdydTynehX4Q4UuT0bfjeaum8otdnguC7HF1ouyMHcYB4g1aVipEhv5oHO68QzGWJvGqTZtj7Ub5GSqLudOXUWOMxfWQZxVaMsQbZlDW5Z47OnyM-OqmMmZs3cJkMuZVIjcvVFOPmW1XstQTEMxg4IQY22Zk6BgqO8jyAjyyGPbDQ6zWjtOs1MQeuzRchj1Gm1WycKUc5xD1oGaG4DHblfoX0oSAh0eiEOPwQovVkRdHSlGn13tdEp3JBgUeOxZQ6FTuf69FnfP_hsP2SVkUbbfH-zdY5uBI3hH-LDN1meTubnPLqqvs9F08qDWEZx9PG8-_QIVJq5n |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Design+and+rationale+of+the+Botswana+Smoking+Abstinence+Reinforcement+Trial%3A+a+protocol+for+a+stepped-wedge+cluster+randomized+trial&rft.jtitle=Implementation+science+communications&rft.date=2024-05-08&rft.pub=Springer+Nature+B.V&rft.eissn=2662-2211&rft.volume=5&rft.spage=1&rft_id=info:doi/10.1186%2Fs43058-024-00588-7&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2662-2211&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2662-2211&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2662-2211&client=summon |